# Ascentage Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ascentage-pharma

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.ascentage.cn
- Total disclosed funding: $237M
- Latest round: Series C (Jul 17, 2018)
- Investors on record: 13

## About

Founded in 2009 and based in Suzhou, China, Ascentage Pharma is a biopharmaceutical company that focuses on original drug discovery and development. It has branches in Beijing, Shanghai, Guangzhou, Taizhou, the United States, and Australia. The chairman of the Board, CEO, and co-founder, Dajun Yang is a professor and Ph.D. supervisor at Sun Yat-sen University Cancer Center. The company cooperates with UNITY Biotechnology and MD Anderson Cancer Center. Ascentage Pharma has acquired 16 ODDs(Orphan Drug Designation) from the US FDA(Food and Drug Administration). In October 2019, the company was listed on the Hong Kong Stock Exchange with stock code 6855. In June 2024, Takeda Pharmaceutical acquired 24.307 million shares in the company in a PIPE transaction. In January 2025, it was listed on the NASDAQ.

The company is committed to developing innovative drugs in the fields of oncology, hepatitis B, and age-related diseases. The marketed products include Olverembatinib, which is suitable for chronic myeloid leukemia, acute lymphocytic leukemia, and gastrointestinal stromal tumors. The products under development include Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), and APG-5918. APG-2575 selectively inhibits BCL-2 protein and restores the normal apoptosis process of cancer cells, thereby achieving the goal of treating tumors. It is suitable for small lymphocytic lymphoma and multiple myeloma.

The company generates revenue by providing innovative drugs in the therapeutic areas of oncology, hepatitis B, and aging-related diseases. 

The company will use the IPO funding to seek NDA approval for r/r CLL in China, prepare for commercial release in China, advance clinical development of ofortinib in the United States and other countries, fund research and development of other candidate products for the company's future pipeline projects, as well as working capital and general corporate purposes.

## Funding rounds

- Series C, Jul 17, 2018, $150M — CCB International, Oriza Holdings, ArrowMark Partners, YuanMing Capital, CTS Capital, HDY International Investment, Teng Yue Partners
- Series B, Dec 26, 2016, $72M — Oriza Holdings, CS Capital, YuanMing Capital, Efung Capital, Hidragon Capital, Shiyu Capital
- Series A, Aug 8, 2015, $15M — Oriza Holdings, Grains Valley Venture Capital, YuanBio Venture, YuanMing Capital, Efung Capital

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series A, Series B, Series C
- Grains Valley Venture Capital (https://capitalatlas.ai/funds/grains-valley-venture-capital) — Series A
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series A
- YuanMing Capital (https://capitalatlas.ai/funds/yuanming-capital) — Series A, Series B, Series C
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A, Series B
- CS Capital — Series B
- Hidragon Capital (https://capitalatlas.ai/funds/hidragon-capital) — Series B
- Shiyu Capital (https://capitalatlas.ai/funds/shiyu-capital) — Series B
- CCB International (https://capitalatlas.ai/funds/ccb-international) — Series C
- ArrowMark Partners — Series C
- CTS Capital — Series C
- HDY International Investment — Series C
- Teng Yue Partners (https://capitalatlas.ai/funds/teng-yue-partners) — Series C